FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803473984> ?p ?o ?g. }

• W2803473984 endingPage "353" @default.
• W2803473984 startingPage "341" @default.
• W2803473984 abstract "Here we examine the relationship between achieving different levels of disease activity with tofacitinib (an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis), long-term structural progression, and patient-reported physical function.This was a post hoc analysis of two 24-month, phase III randomized controlled trials in methotrexate (MTX)-naïve (ORAL Start [NCT01039688]) or MTX-inadequate responder (IR) patients (ORAL Scan [NCT00847613]) receiving tofacitinib 5 or 10 mg twice daily as either monotherapy or with background MTX. The modified total Sharp score (mTSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) were analyzed at month 24 according to disease activity at month 6 defined by the Clinical Disease Activity Index (CDAI) or the Disease Activity Score in 28 joints, C-reactive protein (DAS28CRP).Mean changes from baseline in mTSS at month 24 were less in patients with CDAI remission at month 6 than in those with CDAI moderate/high disease activity (MDA/HDA) at month 6. A DAS28CRP of < 1.9 most closely approximated CDAI remission (≤ 2.8). Tofacitinib appeared to inhibit joint damage in the presence of persistent inflammation compared with MTX. More patients receiving tofacitinib or MTX with CDAI remission or low disease activity (LDA) at month 6 reported normative HAQ-DI scores (< 0.5) at month 24 than did those with CDAI MDA/HDA.Regardless of treatment, in both MTX-naïve and MTX-IR patients, remission or LDA at month 6 was associated with successful long-term outcomes: inhibition of structural progression and normative HAQ-DI scores. Long-term outcomes were similar when patients achieved CDAI remission or a DAS28CRP of < 1.9, confirming that this is an appropriate cut-off for remission with DAS28CRP. Tofacitinib potentially inhibits joint damage even with persistent inflammation.Pfizer Inc.Clinicaltrials.gov identifiers: NCT01039688 and NCT00847613." @default.
• W2803473984 created "2018-06-01" @default.
• W2803473984 creator A5006565253 @default.
• W2803473984 creator A5012283576 @default.
• W2803473984 creator A5022280221 @default.
• W2803473984 creator A5022466985 @default.
• W2803473984 creator A5032135755 @default.
• W2803473984 creator A5058110978 @default.
• W2803473984 creator A5074629207 @default.
• W2803473984 creator A5082669130 @default.
• W2803473984 creator A5089158758 @default.
• W2803473984 creator A5090337589 @default.
• W2803473984 creator A5090753435 @default.
• W2803473984 date "2018-05-14" @default.
• W2803473984 modified "2023-10-17" @default.
• W2803473984 title "Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses" @default.
• W2803473984 cites W1041331430 @default.
• W2803473984 cites W1807077095 @default.
• W2803473984 cites W1974321634 @default.
• W2803473984 cites W1990105300 @default.
• W2803473984 cites W2014330392 @default.
• W2803473984 cites W2026720490 @default.
• W2803473984 cites W2031388906 @default.
• W2803473984 cites W2035320881 @default.
• W2803473984 cites W2038992287 @default.
• W2803473984 cites W2046744512 @default.
• W2803473984 cites W2061785558 @default.
• W2803473984 cites W2069302785 @default.
• W2803473984 cites W2101217991 @default.
• W2803473984 cites W2120393706 @default.
• W2803473984 cites W2129948300 @default.
• W2803473984 cites W2142004396 @default.
• W2803473984 cites W2148357532 @default.
• W2803473984 cites W2149447280 @default.
• W2803473984 cites W2152348310 @default.
• W2803473984 cites W2153414586 @default.
• W2803473984 cites W2164858045 @default.
• W2803473984 cites W2168645087 @default.
• W2803473984 cites W2329207709 @default.
• W2803473984 cites W2344174939 @default.
• W2803473984 cites W2415518156 @default.
• W2803473984 cites W2619420016 @default.
• W2803473984 cites W4210768724 @default.
• W2803473984 cites W4211111012 @default.
• W2803473984 cites W4240504481 @default.
• W2803473984 doi "https://doi.org/10.1007/s40744-018-0113-7" @default.
• W2803473984 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6251846" @default.
• W2803473984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29761420" @default.
• W2803473984 hasPublicationYear "2018" @default.
• W2803473984 type Work @default.
• W2803473984 sameAs 2803473984 @default.
• W2803473984 citedByCount "9" @default.
• W2803473984 countsByYear W28034739842018 @default.
• W2803473984 countsByYear W28034739842019 @default.
• W2803473984 countsByYear W28034739842020 @default.
• W2803473984 countsByYear W28034739842021 @default.
• W2803473984 countsByYear W28034739842022 @default.
• W2803473984 countsByYear W28034739842023 @default.
• W2803473984 crossrefType "journal-article" @default.
• W2803473984 hasAuthorship W2803473984A5006565253 @default.
• W2803473984 hasAuthorship W2803473984A5012283576 @default.
• W2803473984 hasAuthorship W2803473984A5022280221 @default.
• W2803473984 hasAuthorship W2803473984A5022466985 @default.
• W2803473984 hasAuthorship W2803473984A5032135755 @default.
• W2803473984 hasAuthorship W2803473984A5058110978 @default.
• W2803473984 hasAuthorship W2803473984A5074629207 @default.
• W2803473984 hasAuthorship W2803473984A5082669130 @default.
• W2803473984 hasAuthorship W2803473984A5089158758 @default.
• W2803473984 hasAuthorship W2803473984A5090337589 @default.
• W2803473984 hasAuthorship W2803473984A5090753435 @default.
• W2803473984 hasBestOaLocation W28034739841 @default.
• W2803473984 hasConcept C126322002 @default.
• W2803473984 hasConcept C1862650 @default.
• W2803473984 hasConcept C2776233030 @default.
• W2803473984 hasConcept C2777138892 @default.
• W2803473984 hasConcept C2777575956 @default.
• W2803473984 hasConcept C2778886723 @default.
• W2803473984 hasConcept C2779134260 @default.
• W2803473984 hasConcept C2781059491 @default.
• W2803473984 hasConcept C67761136 @default.
• W2803473984 hasConcept C71924100 @default.
• W2803473984 hasConcept C90924648 @default.
• W2803473984 hasConceptScore W2803473984C126322002 @default.
• W2803473984 hasConceptScore W2803473984C1862650 @default.
• W2803473984 hasConceptScore W2803473984C2776233030 @default.
• W2803473984 hasConceptScore W2803473984C2777138892 @default.
• W2803473984 hasConceptScore W2803473984C2777575956 @default.
• W2803473984 hasConceptScore W2803473984C2778886723 @default.
• W2803473984 hasConceptScore W2803473984C2779134260 @default.
• W2803473984 hasConceptScore W2803473984C2781059491 @default.
• W2803473984 hasConceptScore W2803473984C67761136 @default.
• W2803473984 hasConceptScore W2803473984C71924100 @default.
• W2803473984 hasConceptScore W2803473984C90924648 @default.
• W2803473984 hasIssue "2" @default.
• W2803473984 hasLocation W28034739841 @default.
• W2803473984 hasLocation W28034739842 @default.
• W2803473984 hasLocation W28034739843 @default.
• W2803473984 hasLocation W28034739844 @default.

• next